Novavax, Inc.

As of June 30, 2026, Novavax, Inc. carries a market capitalization of 1.14B, placing it among publicly traded companies globally. Its enterprise value stands at 797.15M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Novavax, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Novavax, Inc. has 164.82M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 3.37, and the price-to-book ratio stands at -7.39.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 797.15M versus a market cap of 1.14B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Novavax, Inc. maintains a current ratio of 2.33, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -155.90, indicating conservative leverage, while an interest coverage ratio of -9.88 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -21.62, reflecting losses generated across the asset base. The company generates approximately 417,976.65 in revenue per employee across its workforce of 799.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.75 indicates how many times Novavax, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Novavax, Inc. recorded 1.95M in income tax expense. The company reported a pretax loss of -198.17M and -200.12M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 9, 2026, Novavax, Inc.'s stock has gained approximately 29.31% over the past 52 weeks. The 50-day moving average sits at 7.36, while the 200-day moving average is 8.82.

Over the twelve months ended June 30, 2026, Novavax, Inc. generated 334.28M in revenue and converted that into -200.12M in net income, yielding earnings per share of -1.22. EBITDA reached -174.73M, while operating income came in at -110.09M.

As of June 30, 2026, Novavax, Inc. holds 581.10M in cash and equivalents against 240.18M in total debt, resulting in a net debt position of 80.81M. Total book value stands at -154.06M, with working capital of 355.87M providing operational flexibility.

Novavax, Inc. produced -29.81M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Novavax, Inc. posted a gross margin of 78.60, reflecting its pricing power and cost economics. The operating margin of -32.93 and net profit margin of -59.87 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.63: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -5.30, meaning Novavax, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Novavax, Inc.'s most recent stock split took place on May 10, 2019 with a 20:1 split ratio.

As of June 30, 2026, Novavax, Inc. has an Altman Z-Score of -6.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.